DUBLIN--(BUSINESS WIRE)--The "Cytomegalovirus (CMV) Infections - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CMV in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Cytomegalovirus (CMV) Infections from 2016 to 2027 segmented by seven major markets.
The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The Cytomegalovirus (CMV) Infections market report gives the thorough understanding of the Cytomegalovirus (CMV) Infections by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cytomegalovirus (CMV) Infections in the US, Europe, and Japan.
The Cytomegalovirus (CMV) Infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Sero Prevalence of Cytomegalovirus Infection in 7MM, Total Diagnosed CMV Patients in 7MM, Infants at High Risk of CMV, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT), Number of Refractory CMV Patients after HSCT, Number of CMV Patients among Solid Organ Transplants (SOT), CMV Retinitis among HIV Patients) scenario of Cytomegalovirus (CMV) Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to research, the total sero-prevalent population of Cytomegalovirus (CMV) Infections was found to be 162,856,267 in the US in 2016.
- Clinigen Group Plc
- CSL Behring
- Gilead Sciences
- Merck & Co.
- Biotest AG
- Shire Pharmaceuticals
- Atara Bio therapeutics
- Astellas Pharma Global Development Inc.
- Chimerix Inc.
Key Topics Covered
1. Key Insights
2. Cytomegalovirus (CMV) Infections (TSC) Market Overview at a Glance
3. Disease Overview: Cytomegalovirus (CMV) Infections (TSC)
4. Epidemiology and Patient Population
5. 7MM Total Prevalent Patient Population of Cytomegalovirus (CMV) Infections
6. Country Wise-Epidemiology of Cytomegalovirus (CMV) Infections
7. Current Treatment Practices
8. Unmet Needs
9. Marketed drugs
10. Emerging Therapies
11. Cytomegalovirus (CMV) Infections: 7 Major Market Analysis
12. Market Outlook by Country
13. The United States: Market Outlook
14. EU-5 Countries: Market Outlook
15. Market Drivers
16. Market Barriers
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fr3z99/cytomegalovirus?w=4